Visanne Post-approval Observational Study (VIPOS)

NCT01266421 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27840

Last updated 2020-07-29

No results posted yet for this study

Summary

The study assesses safety aspects of Dienogest (DNG) 2mg/day (Visanne) used as endometriosis therapy and of other hormonal treatments for endometriosis.

Conditions

  • Endometriosis

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY
  • Center for Epidemiology and Health Research, Germany

    lead OTHER

Principal Investigators

  • Klaas Heinemann, PhD, MD, MBA · Center for Epidemiology and Health Research

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-07
Primary Completion
2018-10-31
Completion
2019-01-26

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266421 on ClinicalTrials.gov